Advertisement
Tony Colasin was former Sr. Director of Business Development for ICOSCorporation. From January 2001 to January 2007, he directed that company'sbusiness development during several major product introductions. Mr. Colasinmanaged M&A investment banking engagements, establishing ascreening/evaluation process. He led the development and implementation ofICOS' product licensing review process and standardized valuation techniques(NPV and option valuation), which increased the number of opportunitiesassessed annually and improved overall capacity for revenue.
Advertisement
Notably, Tony Colasin was responsible for building a urology franchise toleverage the Cialis(R) brand, a treatment for erectile dysfunctionsuccessfully launched against Viagra(R). Mr. Colasin led a team that createdan integrated business development strategy for the company's urologyfranchise and was a member of the Cialis(R) pre-commercialization team createdto develop ICOS sales force's strategy/configuration and pre-launch activitiesto establish brand character.
While at ICOS Corporation, he also secured a co-promotion agreement ofAndrogel: successfully led the cross-functional effort to identify productscomplementary to Cialis(R) and negotiated and executed a multi-million dollarco-promotion agreement for the ICOS sales force. He is also attributed withnegotiating rights to a drug used to treat chronic painful bladder syndromevalued at over $25 million, and establishing a $68 million+ strategic allianceand cross-license agreement with a large, potentially competitivebiotechnology company.
Prior to ICOS Corporation, Mr. Colasin was Sr. Finance Manager, CorporateFinance, for Amgen, Inc. from November 1998 to December 2000. He was a memberof Amgen's cross-functional team responsible for the evaluation of drugcandidates and management of marketed products for the company's OncologyFranchise. He developed a strong team and led commercial evaluation ofoncology-related licensing efforts; he was the finance representativeresponsible for managing research, a third-party international partnership,and he supported M&A efforts including evaluation of acquisition targets,identifying comparables, determining optimal financing strategy, andsupporting SEC filing efforts.
His position as Sr. Finance Manager followed Mr. Colasin's earliercontributions to Amgen as Marketing Manager, from July 1997 to October 1998,and Financial Analyst for the $1 billion+ drug EPOGEN(R), from February 1996to June 1997. In his early roles with the company, he played a vital part inanalyzing forecasts, financial models and sales trends critical to productsand markets that the company was pursuing.
Mr. Colasin's initial analyst career was as Sr. Analyst for Putnam, Hayes& Bartlett, Inc., an economic and management consulting firm. With the firm,he diagnosed problems, created analytical frameworks, conducted analyses,developed conclusions, and presented recommendations to senior clientmanagement. He also provided analytical support to clients involved in abillion dollar+ licensing agreement dispute, including issues related toreimbursement policies, market penetration and product distribution.
Tony Colasin graduated from University of Southern California with a B.S.,Business Administration and received his M.B.A, Finance in InternationalBusiness Emphasis, in June 2000 from the Anderson School at UCLA.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emergingbiotechnology company engaged in the principle business of the discovery,development and commercialization of breakthrough stem cell enablingthera